![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma |
Jong Hyun Choi, Juwhan Choi, Sang Mi Chung, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Gyu Young Hur, Jae Jeong Shim, Kyung Ho Kang, Hyun Kyung Lee, Sung Yong Lee |
Tuberc Respir Dis. 2019;82(3):211-216. Published online December 20, 2018 DOI: https://doi.org/10.4046/trd.2018.0019 |
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma Weekly docetaxel as first-line therapy for elderly patients with advanced non-small cell lung cancer (NSCLC) Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Renal Impairment Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma P2.01-035 Phase II Study: Weekly Docetaxel as First Line Chemotherapy for Elderly Patients with Squamous-Cell Non-Small-Cell Lung Cancer Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations A phase II study using teniposide (VM26) alone as first line therapy in elderly patients (PTS) affected by Small Cell Lung Cancer (SCLC) |